MRC Technology And Yabao Pharmaceuticals Announce Exclusive Partnership In China To Develop Novel Therapeutics For Parkinson’s Disease
London, UK and Beijing, China, 24 November 2014: MRC Technology, a medical research charity, and Yabao Pharmaceutical Co, Inc., a leading pharmaceutical company in China, today announced an exclusive license agreement to discover, develop and commercialise innovative compounds targeting a specific kinase involved in neurodegeneration, with the aim of developing novel therapeutics for the treatment of Parkinson’s disease.
Under the terms of the agreement, Yabao receives exclusive rights to discover, develop and commercialise the therapeutics in China, Taiwan and Hong Kong whilst MRC Technology retains rights in all other markets. Financial terms have not been disclosed.
Dr Peng Wang, President R&D, Yabao Pharmaceutical Co. said: “Yabao is pleased to be collaborating with MRC Technology, a leading UK research institute focused on improving the lives of patients through medical discovery. This opportunity for us to expand on leading research to develop innovative products is further evidence of Yabao's growing commitment to partner the best science to treat serious diseases in China."
Michael Dalrymple, Director, Business Development at MRC Technology said: “Parkinson’s is a debilitating and destructive disease. We are pleased to combine our expertise in early drug discovery and innovation with the significant resources that Yabao Pharmaceutical Co. can bring to developing ground breaking new medicines. Together we hope to achieve more to bring innovative treatments to patients and improve their quality of life.”
ENDS
Contacts
Media enquiries
Sarah Jeffery
Zyme Communications
E-mail: sarah.jeffery@zymecommunications.com
Phone: +44 (0)7771 730919
At MRC Technology
Liezel Tipper, PR & Communications Manager
E-mail: ltipper@tech.mrc.ac.uk
Phone: +44 (0)20 7391 2772
At Yabao Pharmaceutical Co.
Ms. Weina Liu
E-mail: liuweina@yabaoyaoye.com
Phone: +86-10-5808-6285
Editor’s Notes
About MRC Technology
MRC Technology (www.mrctechnology.org) is an independent life science medical research charity, offering professional services to organisations within the academic, charity, biotechnology and pharmaceutical sectors globally. Services include IP management and research and development for diagnostics, small molecules and therapeutic antibodies. MRC Technology bridges the gap between basic medical research and commercialisation, helping early discoveries progress to clinical application.
Please note MRC Technology has been independent from the UK’s Medical Research Council (MRC) since 2000. About Yabao Pharmaceutical Co.
Yabao Pharmaceutical Co. (www.yabao.com.cn, Shanghai Stock Exchange 600351) is a leading Chinese pharmaceutical company with fully-integrated development, manufacturing, and commercialisation capabilities in China. The company undertakes strategic development of innovative pharmaceuticals in addition to a well-established business in modern traditional Chinese medicines and chemical generics. In addition to strong clinical and regulatory capabilities, Yabao has expertise in formulation and API production and meets good manufacturing practice (cGMP) requirements with a manufacturing site approved by US FDA and another awaiting inspection by the European agency.
Help employers find you! Check out all the jobs and post your resume.
Under the terms of the agreement, Yabao receives exclusive rights to discover, develop and commercialise the therapeutics in China, Taiwan and Hong Kong whilst MRC Technology retains rights in all other markets. Financial terms have not been disclosed.
Dr Peng Wang, President R&D, Yabao Pharmaceutical Co. said: “Yabao is pleased to be collaborating with MRC Technology, a leading UK research institute focused on improving the lives of patients through medical discovery. This opportunity for us to expand on leading research to develop innovative products is further evidence of Yabao's growing commitment to partner the best science to treat serious diseases in China."
Michael Dalrymple, Director, Business Development at MRC Technology said: “Parkinson’s is a debilitating and destructive disease. We are pleased to combine our expertise in early drug discovery and innovation with the significant resources that Yabao Pharmaceutical Co. can bring to developing ground breaking new medicines. Together we hope to achieve more to bring innovative treatments to patients and improve their quality of life.”
ENDS
Contacts
Media enquiries
Sarah Jeffery
Zyme Communications
E-mail: sarah.jeffery@zymecommunications.com
Phone: +44 (0)7771 730919
At MRC Technology
Liezel Tipper, PR & Communications Manager
E-mail: ltipper@tech.mrc.ac.uk
Phone: +44 (0)20 7391 2772
At Yabao Pharmaceutical Co.
Ms. Weina Liu
E-mail: liuweina@yabaoyaoye.com
Phone: +86-10-5808-6285
Editor’s Notes
About MRC Technology
MRC Technology (www.mrctechnology.org) is an independent life science medical research charity, offering professional services to organisations within the academic, charity, biotechnology and pharmaceutical sectors globally. Services include IP management and research and development for diagnostics, small molecules and therapeutic antibodies. MRC Technology bridges the gap between basic medical research and commercialisation, helping early discoveries progress to clinical application.
Please note MRC Technology has been independent from the UK’s Medical Research Council (MRC) since 2000. About Yabao Pharmaceutical Co.
Yabao Pharmaceutical Co. (www.yabao.com.cn, Shanghai Stock Exchange 600351) is a leading Chinese pharmaceutical company with fully-integrated development, manufacturing, and commercialisation capabilities in China. The company undertakes strategic development of innovative pharmaceuticals in addition to a well-established business in modern traditional Chinese medicines and chemical generics. In addition to strong clinical and regulatory capabilities, Yabao has expertise in formulation and API production and meets good manufacturing practice (cGMP) requirements with a manufacturing site approved by US FDA and another awaiting inspection by the European agency.
Help employers find you! Check out all the jobs and post your resume.